BioCentury | Apr 7, 2014
Company News

Bayer sales and marketing update

...Bayer launched Jaydess low-dose levonorgestrel-releasing intrauterine system in the U.K. as a long-term contraceptive. The product, which costs £69.22...
...company said one device can be used for up to three years. Bayer already markets Jaydess...
BioCentury | Jan 21, 2013
Clinical News

Skyla regulatory update

...FDA approved 13.5 mg Skyla levonorgestrel-releasing intrauterine device (IUD) to prevent pregnancy for up to 3...
...The company plans to launch the product next month. Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Skyla...
BioCentury | Dec 10, 2012
Clinical News

Jaydess regulatory update

...Bayer said its Jaydess low-dose levonorgestrel-releasing intrauterine system was approved under the EU's decentralized procedure as a long-term contraceptive...
...under review in the U.S. Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Jaydess ( LCS , low-dose levonorgestrel-releasing intrauterine system...
BioCentury | Dec 19, 2011
Clinical News

Jaydess regulatory update

...releases a constant, low dose of levonorgestrel. Bayer AG (Xetra:BAY), Leverkusen, Germany Product: Jaydess ( LCS...
BioCentury | Sep 18, 2008
Distillery Therapeutics

This Week in Therapeutics

...of bacterial and fungal pathogens all enhanced HIV-1 transmission compared with control medium. Langerhans cells (LCs...
...Further studies are necessary to identify the receptors for the inflammatory cytokines and pathogens on LCs...
BioCentury | Sep 30, 2002
Product Development

The LCS symptoms

...The LCS symptoms Lung Cancer Subscale (LCS) of the Functional Assessment of Cancer Therapy for Lung...
BioCentury | Sep 30, 2002
Product Development

The quality of life debate

...The agency twice rejected AZN's requests to use improvement on the Lung Cancer Subscale ( LCS...
...in total LCS score for a minimum of four weeks without interim worsening (see "The LCS...
...of those who received the 250 mg and 500 mg doses, respectively, reported improvements in LCS...
BioCentury | Feb 4, 2002
Company News

University of Keil other research news

...Scientists reported in Nature Medicine that rat ESC-LCs, derived from rat blastocysts, remained viable and engrafted...
Items per page:
1 - 8 of 8